Lyra Therapeutics Lead Drug Candidate Fails in Phase 3 Study

Lyra Therapeutics on Monday said a late-stage study of its lead drug candidate missed its main goal in a chronic inflammatory sinus disorder.

WSJMay 6 20:22

Global Equities Roundup: Market Talk

The latest Market Talks covering Equities. Published exclusively on Dow Jones Newswires throughout the day. 1435 ET - AutoCanada felt the weight of a softer consumer environment, which translated int

WSJ02:35

Trending Stocks Today: Nuvo Group Surges 199.5%

May 6th - US stocks trending in regular trading hours.Gainers: $Nuvo Group(NUVO.US)$ shoots up 199.5% to $6.11 with a turnover of $245.38 million. $Strong Global Entertainment(SGE.US)$ surges 115.77%

Futu News02:00

Crude Oil Gains 1%; TreeHouse Foods Shares Fall After Q1 Results

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 100 points on Monday.The Dow traded up 0.18% to 38,744.60 while the NASDAQ rose 0.69% to 16,267.82. The S&

Benzinga00:48

12 Health Care Stocks Moving In Monday's Intraday Session

GainersNRX Pharmaceuticals (NASDAQ:NRXP) shares increased by 39.5% to $2.93 during Monday's regular session. The company's market cap stands at $30.9 million. TC BioPharm (Holdings) (NASDAQ:TCBP) stoc

Benzinga00:31

Lyra Therapeutics Cut to Neutral From Buy by BTIG

Lyra Therapeutics Cut to Neutral From Buy by BTIG

Dow Jones00:08